Post-Stroke PTSD: The Protective Role of CCR5-Δ32 Polymorphism

Area of Science:

• Neuroscience
• Genetics
• Psychiatry

Background:

• Post-traumatic stress disorder (PTSD) affects up to 25% of stroke survivors, with unknown predisposing factors.
• The C-C-Chemokine receptor-5 gene (CCR5) loss-of-function mutation (CCR5-Δ32) is a known protective factor against post-stroke depression.
• This study explores CCR5-Δ32's protective role against post-stroke PTSD, alongside 5-HTTLPR and BDNF Val66Met variants.

Purpose of the Study:

• To investigate the association between the CCR5-Δ32 polymorphism and the development of PTSD symptoms in ischemic stroke survivors.
• To examine the combined effects of CCR5-Δ32 with other genetic variants (5-HTTLPR, BDNF Val66Met) on PTSD risk.
• To identify potential genetic targets for preventing post-stroke PTSD.

Main Methods:

• Prospective analysis of 432 mild-to-moderate ischemic stroke survivors.
• Assessment of PTSD symptomatology at 6, 12, and 24 months post-stroke.
• Genetic screening for CCR5-Δ32, 5-HTTLPR, and BDNF Val66Met polymorphisms.

Main Results:

• PTSD diagnosed in 11% of participants within the first year.
• CCR5-Δ32 carriers showed significantly fewer PTSD symptoms at all follow-up points (P < .001, P < .001, P = .02).
• CCR5-Δ32 independently associated with lower PTSD risk; combined with 5-HTTLPR-L or BDNF Val allele, further reduced PTSD symptoms.

Conclusions:

• CCR5-Δ32 carriers are less prone to developing PTSD after stroke, even with maladaptive coping styles.
• The CCR5-Δ32 variant represents a potential genetic target for post-stroke PTSD prevention.
• CCR5 blockade emerges as a promising therapeutic strategy for mitigating PTSD in stroke survivors.